InsiderTradr

Vineet Laboratories Limited (VINEETLAB.NS)

NSE · INR · Basic Materials · Chemicals

₹36.79 (-1.50%) as of

Key statistics

Market cap
706.60M
P/E (TTM)
15.08
EPS (TTM)
2.44
Dividend yield
0.00%
52-week range
27.96 – 49.99
Beta
0.21
Revenue (TTM)
595.05M
Profit margin
1.87%
Volume
106.30k

About Vineet Laboratories Limited

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Sector
Basic Materials
Industry
Chemicals
Headquarters
Hyderabad, India

vineetlabs.co.in

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks